Moleculin Biotech (NASDAQ:MBRX) Enters Into Warrant Exercise Inducement Agreement
On February 13, 2025, Moleculin Biotech, Inc. filed a Form 8-K with the Securities and Exchange Commission, announcing the company’s entry into a warrant exercise inducement offer letter. The letter, which was signed with a holder of specific existing warrants, entails the issuance of new warrants, termed as the “Inducement Warrants.” The agreement outlined that […]
On February 13, 2025, Moleculin Biotech, Inc. filed a Form 8-K with the Securities and Exchange Commission, announcing the company’s entry into a warrant exercise inducement offer letter. The letter, which was signed with a holder of specific existing warrants, entails the issuance of new warrants, termed as the “Inducement Warrants.” The agreement outlined that […]
